PLATE · THE DOSE-CONTEXT RECORD
BPC-157 TB-500 Dosage as Recorded in the Research Literature
There is no validated dose for the blend. What exists are component-level figures from animal models, kept here as a research-context record — what was given, to which species, by which route — and not as guidance for any person.
BPC-157 TB-500 dosage in the research literature
BPC-157 TB-500 dosage has no validated figure for the blend itself. No peer-reviewed combination dose-finding study exists. Commercial research-product labeling commonly pairs the two at fixed combined masses per vial — for example ~10 mg BPC-157 with ~10 mg TB-500, or a 20 mg combined vial — but no standardized composition or ratio is clinically validated. The figures below are research-context, drawn from animal studies of each component separately, and are not guidance for any person.
The BPC-157 component, in rodent models, is commonly expressed per body weight — frequently around 10 microg/kg and 10 ng/kg, with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats [1]. Note the unit span: the tendon work used microgram- and nanogram-per-kilogram figures [1], several orders of magnitude below the milligram-per-vial masses on commercial blend labels. A vial mass is not a dose, and the two cannot be reconciled into human guidance.
The TB-500 / Thymosin Beta-4 component spans a wide range in animal work — and the range carries its own lesson. The marketed loading logic of "more is better" does not hold in the underlying studies: in a rat embolic-stroke dose-response study, intraperitoneal Thymosin Beta-4 was tested across 2-18 mg/kg, and the response was non-monotonic, with the highest 18 mg/kg dose giving no benefit [4]. Higher was not better. Human single-agent reference points exist only for full-length Thymosin Beta-4, not the heptapeptide and not the blend [5]. Community loading-then-maintenance blend protocols have no controlled-trial basis [8].
How often should you inject BPC-157 and TB-500?
There is no validated dosing schedule for the blend; community "loading then maintenance" protocols have no controlled-trial basis [8]. Research doses are reported per body weight in animal models only [1] [4], and a rodent dosing interval is not a human schedule.
How do you cycle BPC-157 and TB-500?
No validated cycling protocol exists. Fixed-ratio vials (for example 10 mg + 10 mg) and loading/maintenance schedules circulate in the community without any controlled human-trial basis, and the one dose-response study available shows the highest dose can give no benefit [4] [8].
Routes studied for the blend constituents
The routes most people associate with the Wolverine blend are not the routes that generated its evidence, and the gap is worth drawing. The predominant routes in the rodent efficacy studies for both peptides were intraperitoneal [1] [4]; intravenous was used in human Phase 1 work on full-length Thymosin Beta-4 and in a BPC-157 safety pilot [5]. Subcutaneous and intramuscular are the predominant research-community routes for the blend, and they are not drawn from controlled human efficacy trials.
That is the answer behind the common "wolverine injection" question: subcutaneous and intramuscular injection are what the community uses, but the human efficacy basis for those routes — for the combination specifically — does not exist [7].
Oral versus injected administration {#bpc-157-tb-500-oral}
The "bpc 157 tb 500 oral" question rests mostly on BPC-157, which is studied as a stable gastric peptide — the reason oral BPC-157 is even discussed [1]. Blend oral products are marketed but lack validated pharmacokinetics, and the oral behavior of the Ac-LKKTETQ heptapeptide is not characterized at all. Injected routes — subcutaneous, intramuscular, intraperitoneal — dominate both community practice and the underlying animal studies. Neither oral nor injected blend dosing has a human efficacy trial behind it [7], so the oral-versus-injected debate is, for the combination, a comparison between two routes that have never been tested head to head in a controlled human study of the blend.
Half-life, reconstitution, and why a blend dose is undefined
On half-life, the precise figure is short and the honest answer is mostly a gap. BPC-157's elimination half-life was reported as under 30 minutes in animal pharmacokinetics — a brief window that bears on how often the compound was given in animal work, not on any human schedule [1]. No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend [5].
Both constituents are supplied as lyophilized (freeze-dried) powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. A common community practice is to reconstitute the two peptides separately or in a shared vial. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated Wolverine material are not guaranteed — so even where a label prints two masses, the contents are not independently verified outside formal study conditions [5].
That uncertainty compounds an existing identity gap. TB-500 as sold is the Ac-LKKTETQ heptapeptide (~889.02 Da), but most efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da) [5]. A blend dose would have to specify not just two masses and a ratio, but which TB-500 the data even refer to — and no study does. This page is research context, not guidance: it describes what was administered to which species at which dose by which route, and stops there. For the regulatory position, see the Wolverine legal status and FDA 503A compounding access page; for the side effects and the tumor-angiogenesis safety signal, see the frequently asked questions about the blend.
What is the half-life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported as under 30 minutes in animal pharmacokinetics [1]. No validated human half-life exists for either constituent at research doses, and none for the blend [5].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [5]. This describes research handling, not a preparation instruction for human use.